Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
Cardiovascular Complications of Novel Multiple Myeloma Treatments | Circulation
Carfilzomib in multiple myeloma | PPT
Healthcare reality of the treatment of the high-risk multiple myeloma in Spain | Medicina Clínica (English Edition)
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Frontiers | Therapeutic strategies to enhance immune response induced by multiple myeloma cells
Emerging immunotherapies in multiple myeloma | The BMJ
Multiple myeloma | Nature Reviews Disease Primers
Patient characteristics of 130 relapse and refractory multiple myeloma... | Download Scientific Diagram
Amgen's Phase III ASPIRE trial of myeloma treatment Kyprolis meets primary endpoint - Clinical Trials Arena
Cells | Free Full-Text | Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications
Emerging immunotherapies in multiple myeloma | The BMJ
Additional Abstracts of Interest in Multiple Myeloma at ASH 2015 | Research To Practice
Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France — a cohort study using the French National Healthcare database (SNDS) | Annals of Hematology
Biomedicines | Free Full-Text | Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting
Clinical Trials in R/R Multiple Myeloma
Efficacy and safety of carfilzomib for the treatment of multiple myeloma: An overview of systematic reviews - ScienceDirect
Kyprolis® Treatment for Patients With Multiple Myeloma - CancerConnect
Carfilzomib in multiple myeloma | PPT
Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost | International Journal of Hematology
How I treat high-risk multiple myeloma - ScienceDirect
Multiple #Myeloma is a... - Dr. Reddy's Laboratories Ltd. | Facebook
Dr. Reddy's Laboratories Ltd. - Multiple myeloma is a cancer of plasma cells that generally affects people in the age group of 52-61 years and early diagnosis is possible with routine blood
Cancers | Free Full-Text | Genome Instability in Multiple Myeloma: Facts and Factors
Multiple myeloma treatment and management in the elderly. | Semantic Scholar